Nodakenin represses obesity and its complications via the inhibition of the VLDLR signalling pathway in vivo and in vitro.

These results demonstrate the potential of NK as a natural product-based therapeutic candidate for the treatment of obesity and its complications by targeting adipogenesis and adipose tissue inflammation-associated markers.